Ferric carboxymaltose lowered a combined heart-failure outcome, with mortality effects uncertain
The pooled trials favored ferric carboxymaltose for hospitalization or cardiovascular death together; separate analyses of hospitalization and death did not reach statistical significance.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among people with heart failure and iron deficiency, ferric carboxymaltose reduced the combined risk of hospitalization for heart failure or cardiovascular death compared with controls. The separate hospitalization and mortality analyses were not statistically significant. This supports a benefit on the combined outcome, while leaving uncertain whether treatment reduces deaths or hospitalizations considered individually.
This abstract-based summary cannot assess absolute benefit or detailed safety: event rates, follow-up durations and safety results were not provided. Those omissions limit interpretation of the treatment's practical impact.
What researchers found
Heart-failure hospitalization or cardiovascular death
With ferric carboxymaltose, risk was 0.86 times the control group's risk. This is a relative comparison; follow-up duration was not reported in the abstract.
How the combined endpoint works
The main endpoint counted either a heart-failure hospital admission or a cardiovascular death. Pooling these events produced a statistically significant result, even though the separate analyses did not establish differences in either component.
Interpreting the mortality findings
Neither deaths from cardiovascular causes nor deaths from any cause showed a statistically significant difference. These uncertain results should not be read as proof that the treatments have identical effects on survival.
The original publication
Ferric Carboxymaltose Among Patients with Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Controlled Trials.
Mohamed AE, Gadelmawla AF, Kholeif Z et al.
Cardiovasc Toxicol · 2026
- PubMed ID
- 41524998
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.